HomeAI · summaries
Storia in 2 fonti
Viridian, awaiting FDA decision, taps WuXi Bio in eye drug supply deal
Viridian Therapeutics has spent years moving its thyroid eye disease (TED) hopeful, veligrotug, through clinical trials a | Viridian aims to challenge Amgen in a blockbuster market, and it's now tapped Chinese CDMO giant WuXi Biologics in a manufacturing pact.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
fiercepharma.com
After prior FDA manufacturing snub, Gilead's hepatitis D med Hepcludex nabs US nod
More than three years after Gilead Sciences’ hepatitis D drug bulevirtide was rebuffed by the FDA on manufacturing and delivery concerns, the treatment has redeemed itself by…
- ·
Outlook moves toward potential US nod for thrice-snubbed eye drug with FDA appeal win
Outlook Therapeutics has notched a win in its uphill battle to commercialize an ophthalmic version of Roche’s Avastin (bevacizumab) in the U.S., with the FDA now agreeing that the…
